Release date: 30 July 2018
EDUCATIONAL OBJECTIVES
TARGET AUDIENCE
PROGRAMME OVERVIEW
In this activity, Highlights from EULAR 2018: Current and Future Perspectives in the Cytokine Signalling Blockade, a panel of international experts discuss key abstracts and data from EULAR 2018, specifically relating to cytokine signalling science.
JAK inhibitors are now being marketed for the treatment of rheumatoid arthritis, and new data are showing how these agents perform in clinical practice. It is also exciting to see on how these agents could be used in the clinic for other indications beyond rheumatoid arthritis. There is, therefore, an educational need to keep up-to-date with ongoing research to understand the impact of these latest data on both current and future clinical practice.
In addition, with the considerable data continuing to be published on JAK inhibition, not only with Phase 2/3 data of newer JAK inhibitors, but also with basic science data providing novel insights into cytokine signalling, it is of increasing importance to stay abreast of the latest information that is available, since applying this knowledge may make a difference to patients in the clinic.
This course, Highlights from EULAR 2018: Current and Future Perspectives in the Cytokine Signalling Blockade outlines recent developments in cytokine signalling science, and highlights the importance of these new data for clinical practice. The learner’s understanding of the information presented will be assessed following each of the course modules.
INSTRUCTIONS FOR PARTICIPATION
DISCLOSURE OF CONFLICTS OF INTEREST
View congress highlights
Module | Presenter | Video | Questions |
---|---|---|---|
Introduction |
Professor Philip Mease
Director and Professor of Medicine, Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates. Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology. As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group. Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology. |
02:14 | |
Clinical Data on Marketed Cytokine Signaling Agents in Rheumatoid Arthritis |
Professor Philip Mease
Director and Professor of Medicine, Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates. Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology. As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group. Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.
Professor Kurt de Vlam
Professor and Principal Investigator , Kurt de Vlam is a Principal Investigator in Rheumatology at the University Hospitals Leuven, Belgium. Professor de Vlam obtained his medical degree, rheumatology specialization, and PhD from Ghent University, Belgium. He then joined University Hospitals Leuven, where he is currently the group leader for spondyloarthropathies and psoriatic arthritis, responsible for a specialized outpatient clinic for spondyloarthropathies and psoriatic arthritis. Professor de Vlam is also a visiting Professor at the 4th Military Medical University Xi’an, in Xi’an, China. As well as conducting clinical trials, Professor de Vlam is the founder of the spondyloarthritis registries SPAR and BIOSPAR, databases at the Rheumatology Department of the University Hospitals Leuven. He is also a Principal Investigator for the BEPASS cohort, a longitudinal observational cohort in psoriatic arthritis in Belgium. Professor de Vlam’s research interest include biomechanics, pathological bone formation, rare bone and joint diseases, eHealth applications, as well as the development and implementation of early phase and late phase clinical trials. |
15:30 | 5 |
New Indications for Cytokine Signaling Agents - Psoriatic Arthritis and Beyond |
Professor Philip Mease
Director and Professor of Medicine, Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates. Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology. As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group. Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.
Professor Thomas Huizinga
Director and Professor of Medicine, Thomas Huizinga is Professor of Rheumatology, Department Head of Rheumatology, and Vice-clinical Educator of Rheumatology at Leiden University Medical Center, Leiden, Netherlands. He is also Chairman of the ‘Meteor’ foundation, an international registry of rheumatoid arthritis disease activity and medication use in more than 20 countries, and is also Chairman of the National Postgraduate Educational Committee of Dutch Rheumatology. Professor Huizinga completed medical school and his doctorate research at the University of Amsterdam. He subsequently studied at Dartmouth Medical School, New Hampshire, US, and then specialised as a rheumatologist at Leiden University Medical Center, where he became a full Professor of Rheumatology in 2000. For more than 30 years, Professor Huizinga has carried out research on pathogenesis, diagnostics and treatment of rheumatological disorders. He has published more than 750 scientific publications and more than 20 book chapters. He has also served on the editorial boards of many journals including Plos Medicine, Annals of Rheumatic Diseases, and Arthritis Rheumatism. Professor Huizinga has participated in a number of international scientific committees, including those that established the 2010 ACR-EULAR criteria for RA, and the EULAR guidelines for the treatment of rheumatoid arthritis. He has been awarded with a number of prizes including in 1997 the EULAR young investigator award, in 2009 the ‘Willy van Heuman award for generation of in vitro models as alternatives for animal models’, and in 2011 the ‘Eurolife Distinguished Faculty Lecture Medal’ by the Karolinska Institut in Stockholm, Sweden. |
20:13 | 4 |
Novel Insights and New Agents in Cytokine Signalling |
Professor Philip Mease
Director and Professor of Medicine, Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates. Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology. As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group. Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.
Professor Thomas Huizinga
Director and Professor of Medicine, Thomas Huizinga is Professor of Rheumatology, Department Head of Rheumatology, and Vice-clinical Educator of Rheumatology at Leiden University Medical Center, Leiden, Netherlands. He is also Chairman of the ‘Meteor’ foundation, an international registry of rheumatoid arthritis disease activity and medication use in more than 20 countries, and is also Chairman of the National Postgraduate Educational Committee of Dutch Rheumatology. Professor Huizinga completed medical school and his doctorate research at the University of Amsterdam. He subsequently studied at Dartmouth Medical School, New Hampshire, US, and then specialised as a rheumatologist at Leiden University Medical Center, where he became a full Professor of Rheumatology in 2000. For more than 30 years, Professor Huizinga has carried out research on pathogenesis, diagnostics and treatment of rheumatological disorders. He has published more than 750 scientific publications and more than 20 book chapters. He has also served on the editorial boards of many journals including Plos Medicine, Annals of Rheumatic Diseases, and Arthritis Rheumatism. Professor Huizinga has participated in a number of international scientific committees, including those that established the 2010 ACR-EULAR criteria for RA, and the EULAR guidelines for the treatment of rheumatoid arthritis. He has been awarded with a number of prizes including in 1997 the EULAR young investigator award, in 2009 the ‘Willy van Heuman award for generation of in vitro models as alternatives for animal models’, and in 2011 the ‘Eurolife Distinguished Faculty Lecture Medal’ by the Karolinska Institut in Stockholm, Sweden.
Professor Kurt de Vlam
Professor and Principal Investigator , Kurt de Vlam is a Principal Investigator in Rheumatology at the University Hospitals Leuven, Belgium. Professor de Vlam obtained his medical degree, rheumatology specialization, and PhD from Ghent University, Belgium. He then joined University Hospitals Leuven, where he is currently the group leader for spondyloarthropathies and psoriatic arthritis, responsible for a specialized outpatient clinic for spondyloarthropathies and psoriatic arthritis. Professor de Vlam is also a visiting Professor at the 4th Military Medical University Xi’an, in Xi’an, China. As well as conducting clinical trials, Professor de Vlam is the founder of the spondyloarthritis registries SPAR and BIOSPAR, databases at the Rheumatology Department of the University Hospitals Leuven. He is also a Principal Investigator for the BEPASS cohort, a longitudinal observational cohort in psoriatic arthritis in Belgium. Professor de Vlam’s research interest include biomechanics, pathological bone formation, rare bone and joint diseases, eHealth applications, as well as the development and implementation of early phase and late phase clinical trials. |
27:48 | 7 |
Close |
Professor Philip Mease
Director and Professor of Medicine, Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates. Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology. As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group. Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology. |
00:57 | |
Evaluation | 17 |
Date of preparation: 20 July 2018